361 related articles for article (PubMed ID: 19071890)
21. Susceptibilities to amphotericin B, fluconazole and voriconazole of Trichosporon clinical isolates.
Tsai MS; Yang YL; Wang AH; Wang LS; Lu DC; Liou CH; Hsieh LY; Wu CJ; Cheng MF; Shi ZY; Lo HJ
Mycopathologia; 2012 Aug; 174(2):121-30. PubMed ID: 22318636
[TBL] [Abstract][Full Text] [Related]
22. Molecular and antifungal susceptibility study on trichosporonemia and emergence of Trichosporon mycotoxinivorans as a bloodstream pathogen.
Dabas Y; Xess I; Kale P
Med Mycol; 2017 Jul; 55(5):518-527. PubMed ID: 27816903
[TBL] [Abstract][Full Text] [Related]
23. Breakthrough infection of Trichosporon asahii during posaconazole treatment in a patient with acute myeloid leukaemia.
Rieger C; Geiger S; Herold T; Nickenig C; Ostermann H
Eur J Clin Microbiol Infect Dis; 2007 Nov; 26(11):843-5. PubMed ID: 17690928
[TBL] [Abstract][Full Text] [Related]
24. Isolation and antifungal susceptibility testing of Trichosporon asahii in Ceará, Brazil.
Menezes EA; Marinho JA; Angelo MR; Cunha Mda C; Cunha FA; Vasconcelos Júnior AA
Rev Inst Med Trop Sao Paulo; 2012; 54(1):1-3. PubMed ID: 22370746
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the microdilution, Etest and disk diffusion methods for antifungal susceptibility testing of clinical strains of Trichosporon spp.
Metin DY; Hilmioglu-Polat S; Hakim F; Inci R; Tumbay E
J Chemother; 2005 Aug; 17(4):404-8. PubMed ID: 16167520
[TBL] [Abstract][Full Text] [Related]
26. Genotype, antifungal susceptibility, and biofilm formation of Trichosporon asahii isolated from the urine of hospitalized patients.
Almeida AA; Crispim Bdo A; Grisolia AB; Svidzinski TI; Ortolani LG; Oliveira KM
Rev Argent Microbiol; 2016; 48(1):62-6. PubMed ID: 26916812
[TBL] [Abstract][Full Text] [Related]
27. Susceptibility patterns and molecular identification of Trichosporon species.
Rodriguez-Tudela JL; Diaz-Guerra TM; Mellado E; Cano V; Tapia C; Perkins A; Gomez-Lopez A; Rodero L; Cuenca-Estrella M
Antimicrob Agents Chemother; 2005 Oct; 49(10):4026-34. PubMed ID: 16189076
[TBL] [Abstract][Full Text] [Related]
28. [Fungemia due to Trichosporon asahii in a patient with hematological malignancy].
Odero V; Galán-Sánchez F; García-Agudo L; García-Tapia AM; Guerrero-Lozano I; Rodríguez-Iglesias MA
Rev Iberoam Micol; 2015; 32(1):59-61. PubMed ID: 24071639
[TBL] [Abstract][Full Text] [Related]
29. Multidrug-resistant Trichosporon asahii infection of nongranulocytopenic patients in three intensive care units.
Wolf DG; Falk R; Hacham M; Theelen B; Boekhout T; Scorzetti G; Shapiro M; Block C; Salkin IF; Polacheck I
J Clin Microbiol; 2001 Dec; 39(12):4420-5. PubMed ID: 11724855
[TBL] [Abstract][Full Text] [Related]
30. Mixed Infection of Toe Nail Caused by Trichosporon asahii and Rhodotorula mucilaginosa.
Idris NFB; Huang G; Jia Q; Yuan L; Li Y; Tu Z
Mycopathologia; 2020 Apr; 185(2):373-376. PubMed ID: 31760556
[TBL] [Abstract][Full Text] [Related]
31. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin.
Matsue K; Uryu H; Koseki M; Asada N; Takeuchi M
Clin Infect Dis; 2006 Mar; 42(6):753-7. PubMed ID: 16477548
[TBL] [Abstract][Full Text] [Related]
32. MALDI-TOF MS characterisation, genetic diversity and antifungal susceptibility of Trichosporon species from Iranian clinical samples.
Ahangarkani F; Ilkit M; Vaseghi N; Zahedi N; Zomorodian K; Khodavaisy S; Afsarian MH; Abbasi K; de Groot T; Meis JF; Badali H
Mycoses; 2021 Aug; 64(8):918-925. PubMed ID: 33998718
[TBL] [Abstract][Full Text] [Related]
33. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
Fera MT; La Camera E; De Sarro A
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
[TBL] [Abstract][Full Text] [Related]
34. Biofilm formation and antifungal susceptibility of Trichosporon asahii isolates from Mexican patients.
Montoya AM; Elizondo-Zertuche M; Treviño-Rangel RJ; Becerril-García M; González GM
Rev Iberoam Micol; 2018; 35(1):22-26. PubMed ID: 29287630
[TBL] [Abstract][Full Text] [Related]
35. In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species.
Thompson GR; Wiederhold NP; Sutton DA; Fothergill A; Patterson TF
J Antimicrob Chemother; 2009 Jul; 64(1):79-83. PubMed ID: 19406849
[TBL] [Abstract][Full Text] [Related]
36. Pathogenicity of Trichosporon asahii in a murine model of disseminated trichosporonosis.
Yang RY; Wang WL; Ao JH; Hao ZF; Zhang J; Wang CM
Chin Med J (Engl); 2008 Dec; 121(24):2557-60. PubMed ID: 19187595
[TBL] [Abstract][Full Text] [Related]
37. First genotype identification of Trichosporon asahii in Sfax, Tunisia.
Sellami H; Trabelsi H; Neji S; Amouri I; Cheikhrouhou F; Makni F; Ayadi A
J Med Microbiol; 2017 Apr; 66(4):397-401. PubMed ID: 28141498
[TBL] [Abstract][Full Text] [Related]
38. [Trichosporon--experience with species identification from human isolates].
Volleková A
Epidemiol Mikrobiol Imunol; 2000 Feb; 49(1):28-33. PubMed ID: 10802949
[TBL] [Abstract][Full Text] [Related]
39. Invasive Infections Due to
Guo LN; Yu SY; Hsueh PR; Al-Hatmi AMS; Meis JF; Hagen F; Xiao M; Wang H; Barresi C; Zhou ML; de Hoog GS; Xu YC
J Clin Microbiol; 2019 Feb; 57(2):. PubMed ID: 30463892
[TBL] [Abstract][Full Text] [Related]
40. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
